"The North American phase III results for MOB-015 are puzzling. A complete cure was achieved in only 4.5% of the patients, well below the company's previously communicated target. However, 70% of patients achieved a mycological cure – which often correlates with a complete cure – surpassing expectations. Thus, even though the overall results were disappointing, we argue that the unusually high difference between the complete and mycological cure rates needs to be further examined before the commercial potential of MOB-015 can be accurately assessed."

Länk till uppdragsanalys nedan.